Back to Search
ERIN RAYBURN, DMD
DMD
General Practice Dentistry
NPI: 1669852588Individual
Specialties, Licenses & Credentials
Research & Publications (20)
FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer.
PMID 19274441·Invest New Drugs·2010
7-preclinical
Synthesis and in vitro anti-lung cancer activity of novel 1, 3, 4, 8-tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogs.
PMID 19442212·Med Chem·2009
7-preclinical
In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues.
PMID 19451594·Clin Cancer Res·2009
7-preclinical
Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action.
PMID 19203832·Cancer Lett·2009
7-preclinical
Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD.
PMID 19131140·Lung Cancer·2009
7-preclinical
Recent advances in validating MDM2 as a cancer target.
PMID 19538162·Anticancer Agents Med Chem·2009
6-review
Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?
PMID 18549978·Drug Discov Today·2008
6-review
Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides.
PMID 18324646·Prostate·2008
4-observational
20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action.
PMID 18253123·Br J Cancer·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 68 KING RD
HATTIESBURG, MS 39402 - Phone
- (601) 951-9021
Quick Facts
- NPI
- 1669852588
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile